[Form 3] Helix Acquisition Corp. II Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Ben Yong filed an initial Form 3 reporting his beneficial ownership in BridgeBio Oncology Therapeutics, Inc. (BBOT). The filing shows two stock options exercisable for common stock: 443,298 shares at an exercise price of $4.17 (exercisable 09/24/2034) and 26,551 shares at $7.88 (exercisable 04/02/2035). Vesting terms are stated: 25% of the larger option vests on September 3, 2025, with the remainder monthly over 36 months; the smaller option vests monthly in 48 equal installments beginning April 4, 2025. The form lists his role as Chief Medical & Development Officer and is signed by an attorney-in-fact on his behalf.

Positive

• Initial Section 16 disclosure filed, providing transparency on executive holdings
• Two stock option awards disclosed with specific exercise prices and vesting schedules
• Officer role identified as Chief Medical & Development Officer, linking the holdings to an executive

Negative

• None.

Insights

Financial Analyst

TL;DR: Officer granted significant option awards with multi-year vesting, aligning compensation with future service.

The filing documents two stock option awards totaling 469,849 underlying shares with fixed exercise prices of $4.17 and $7.88 and long-dated exercisability in 2034 and 2035. Vesting schedules require continued service for multi-year vesting, indicating retention-focused compensation. The absolute size of the larger option (443,298 shares) is notable relative to typical executive grants for a clinical-stage issuer, though the filing does not state outstanding share count or grant date value so materiality to equity dilution cannot be assessed from this form alone.

Corporate Governance Expert

TL;DR: Standard Section 16 disclosure of an officer's option holdings and service-conditioned vesting; no governance red flags disclosed.

The Form 3 correctly discloses the reporting person, officer title, and details of two derivative securities including exercise prices, exercisability dates, and explicit vesting schedules tied to continuous service. The document includes an attorney-in-fact signature and an exhibit reference for a power of attorney. The filing contains the required elements for initial ownership reporting and does not present governance exceptions or unexplained omissions in the disclosed fields.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ben Yong

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Med & Dev Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	09/24/2034	Common Stock	443,298	$4.17	D
Stock Option (Right to Buy)	(2)	04/02/2035	Common Stock	26,551	$7.88	D

Explanation of Responses:

1. 25% of the shares underlying such option shall vest on September 3, 2025, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such vesting date.

2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What securities did Ben Yong report on Form 3 for BBOT?

He reported two stock options exercisable into common stock: 443,298 shares at $4.17 and 26,551 shares at $7.88.

When do the reported stock options become exercisable?

The larger option lists an exercisable date of 09/24/2034 and the smaller option lists 04/02/2035.

What are the vesting terms for the options reported by Ben Yong?

For the 443,298-share option, 25% vests on September 3, 2025 then monthly over 36 months; for the 26,551-share option, 1/48th vests monthly starting April 4, 2025.

What is Ben Yong's relationship to BridgeBio Oncology Therapeutics, Inc. (BBOT)?

The Form 3 lists him as an Officer with the title Chief Medical & Development Officer and also marks him as a Director.

Who signed the Form 3 and when was it signed?

The form is signed by Aaron Chan, Attorney-in-Fact on 08/18/2025.